<DOC>
	<DOCNO>NCT01605318</DOCNO>
	<brief_summary>This Phase I/II , open-label study IMMU-130 administer 21-day treatment cycle , twice weekly 2 consecutive week follow one week rest patient metastatic colorectal cancer previously treat least one prior irinotecan-containing regimen . The study do evaluate whether study drug safe tolerable different dose level dose schedule obtain preliminary information efficacy .</brief_summary>
	<brief_title>Dose Finding Study Once Twice Weekly IMMU-130 Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Male female patient , ≥ 18 year age , able understand give write informed consent . Histologically cytologically confirm colorectal adenocarcinoma . Stage IV ( metastatic ) disease . Previously treat least one prior irinotecancontaining regimen colorectal cancer . Adequate performance status ( ECOG 0 1 ) . ( Appendix 1 ) Expected survival &gt; 6 month . CEA plasma level &gt; 5 ng/mL . Measurable disease CT MRI . At least 4 week beyond treatment ( chemotherapy , immunotherapy and/or radiation therapy ) major surgery recover acute toxicity . At least 2 week beyond corticosteroid . Adequate hematology without ongoing transfusional support ( hemoglobin &gt; 9 g/dL , ANC &gt; 1,500 per mm3 , platelet &gt; 100,000 per mm3 ) . Adequate renal hepatic function ( creatinine ≤ 1.5 x IULN , bilirubin ≤ IULN , AST ALT ≤ 3.0 x IULN 5 x IULN know liver metastasis ) . Otherwise , toxicity study entry ≤ Grade 1 NCI CTC v4.0 . Women pregnant lactating . Women childbearing potential fertile men unwilling use effective contraception study conclusion 12week posttreatment evaluation period . Patients Gilbert 's disease know CNS metastatic disease . Patients CEA plasma level &gt; 1000 ng/mL exclude dose escalation , may include MTD determine . Presence bulky disease ( define single mass &gt; 10 cm great dimension ) . Patients active ≥ grade 2 anorexia , nausea vomiting , and/or sign intestinal obstruction . Patients nonmelanoma skin cancer carcinoma situ cervix eligible , patient prior malignancy must least 3year diseasefree interval . Patients know HIV positive , hepatitis B positive , hepatitis C positive . Known history unstable angina , MI , CHF present within 6 month clinically significant cardiac arrhythmia ( stable atrial fibrillation ) require antiarrhythmia therapy . Known history clinically significant active COPD , moderatetosevere chronic respiratory illness present within 6 month . Infection require intravenous antibiotic use within 1 week . Other concurrent medical psychiatric condition , Investigator 's opinion , may likely confound study interpretation prevent completion study procedure followup examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>previously treat</keyword>
</DOC>